SEC Tracker
Get the app

Lucid Diagnostics LUCD

Lucid Diagnostics raises $15M via Series C Preferred Stock

Item 3.02 Unregistered share sale, Item 3.03 Changes shareholder rights, Item 5.03 Amends charter or bylaws

Form
8-K
Filed
Importance
Notable
  1. Sold 15,000 shares of Series C Preferred Stock at $1,000 per share
  2. Series C Preferred Stock converts to common stock at $0.3519 per share
  3. Dividends of 20% per annum payable in common stock
  4. Series C Preferred Stock is senior to common stock

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Lucid Diagnostics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Apyx Medical APYX public float $80M, Jun 30, 2025
  2. Encision ECIA
  3. Accuray ARAY public float $87M, Dec 31, 2025
  4. TELA Bio TELA public float $77M, Jun 30, 2025
  5. enVVeno Medical NVNO public float $76M, Jun 30, 2025